



Evidence reviews - May 2023

Evidence review

Published: 18 May 2023

www.nice.org.uk

The following documents contain the evidence that was used to develop the May 2023 recommendations:

- [Tranexamic acid](#)
- [Transport to a distant specialist neuroscience centre](#)
- [Direct access from the community to imaging](#)
- [Clinical decision rules selecting people with head injury for imaging](#)
- [Selecting adults, children and infants with head injury for CT or MRI head scan in sub-groups](#)
- [Brain injury biomarkers and/or MRI for predicting post-concussion syndrome](#)
- [Brain injury biomarkers for predicting acute post-brain injury complications](#)
- [CT, MRI and X-ray of the cervical spine in people with head injury – diagnostic](#)
- [Admission and observation in hospital of people with head injury who are on anticoagulant or antiplatelet therapy after normal brain imaging or no indication for early imaging](#)
- [Admission and observation of people with concussion symptoms](#)
- [Hospital admission in people with small intracranial injuries](#)
- [Isolated skull fracture](#)
- [Identification of hypopituitarism \(who to investigate\)](#)
- [Identification of hypopituitarism \(when to investigate\)](#)

Other supporting evidence:

- [Economic analysis on the cost effectiveness of tranexamic acid](#)

Evidence for all other recommendations can be found in the full guideline and supporting appendices:

- [Full guideline](#)
- [Appendices](#)